



Clinical trial results:

A Phase 3b, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects with Immune Thrombocytopenia for 6 Months

Summary

EudraCT number	2020-003232-24
Trial protocol	FR HU DE PL
Global end of trial date	28 October 2025

Results information

Result version number	v2 (current)
This version publication date	23 May 2026
First version publication date	22 May 2024
Version creation reason	• New data added to full data set Trial has finished.
Summary attachment (see zip file)	AVA-PED-301 Lay Language Summary Results (AVA-PED-301 lay language results summary - Final 01Apr2026.docx)

Trial information

Trial identification

Sponsor protocol code	AVA-PED-301
-----------------------	-------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04516967
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Sobi Inc.
Sponsor organisation address	890 Winter Street, Suite 200, Waltham, United States, 02451
Public contact	Medical Information, Sobi, Inc., +1 781 786 7370, medinfo.us@sobi.com
Scientific contact	Medical Information, Sobi, Inc., +1 781 786 7370, medinfo.us@sobi.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-001136-PIP01-11
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	18 November 2025
Is this the analysis of the primary completion data?	Yes
Primary completion date	08 November 2023
Global end of trial reached?	Yes
Global end of trial date	28 October 2025
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To demonstrate that the efficacy of avatrombopag is superior to placebo for the treatment of pediatric subjects with ITP of ≥ 6 months duration who have had an insufficient response to a previous treatment

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) and Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	02 March 2021
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Poland: 4
Country: Number of subjects enrolled	United Kingdom: 13
Country: Number of subjects enrolled	France: 1
Country: Number of subjects enrolled	Germany: 3
Country: Number of subjects enrolled	Hungary: 5
Country: Number of subjects enrolled	United States: 13
Country: Number of subjects enrolled	Russian Federation: 5
Country: Number of subjects enrolled	Ukraine: 2
Country: Number of subjects enrolled	Türkiye: 29
Worldwide total number of subjects	75
EEA total number of subjects	13

Notes:

Subjects enrolled per age group

In utero	0
----------	---

Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	1
Children (2-11 years)	45
Adolescents (12-17 years)	29
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

To be eligible for the study, the subject must have had a confirmed diagnosis of primary ITP for ≥ 6 months duration and had an insufficient response to a previous treatment with an average of 2 platelet counts $< 30 \times 10^9/L$ with no single count $> 35 \times 10^9/L$.

Period 1

Period 1 title	Core Phase
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Avatrombopag
Arm description: -	
Arm type	Experimental
Investigational medicinal product name	Avatrombopag
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for oral suspension, Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received avatrombopag or matching placebo as either the film-coated oral tablet or the powder for oral suspension. The powder for oral suspension was contained in a capsule that was to be opened to sprinkle the contents into an appropriate vehicle to prepare the suspension. No partial dosing from the capsule was allowed; the entire contents were to be used to prepare the suspension. On Day 1, Cohort 1 (≥ 12 to < 18 years old) and Cohort 2 (≥ 6 to < 12 years old) had a starting dose of avatrombopag of 20 mg once daily, administered as an oral tablet, consistent with the approved adult dosing. The starting dose for Cohort 3 (≥ 1 to < 6 years old) was 10 mg once daily administered as an oral suspension. The dose of study drug was to be titrated up or down based on the subject's platelet count to maintain a platelet count between ≥ 50 and $\leq 150 \times 10^9/L$.

Arm title	Placebo
Arm description: -	
Arm type	Placebo
Investigational medicinal product name	Placebo to match avatrombopag
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for oral suspension, Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received avatrombopag or matching placebo as either the film-coated oral tablet or the powder for oral suspension. The powder for oral suspension was contained in a capsule that was to be opened to sprinkle the contents into an appropriate vehicle to prepare the suspension. No partial dosing from the capsule was allowed; the entire contents were to be used to prepare the

suspension. On Day 1, Cohort 1 (≥ 12 to < 18 years old) and Cohort 2 (≥ 6 to < 12 years old) had a starting dose of avatrombopag of 20 mg once daily, administered as an oral tablet, consistent with the approved adult dosing. The starting dose for Cohort 3 (≥ 1 to < 6 years old) was 10 mg once daily administered as an oral suspension. The dose of study drug was to be titrated up or down based on the subject's platelet count to maintain a platelet count between ≥ 50 and $\leq 150 \times 10^9/L$.

Number of subjects in period 1	Avatrombopag	Placebo
Started	54	21
Completed	44	1
Not completed	10	20
Physician decision	1	1
Adverse event, non-fatal	2	1
Lack of efficacy	7	18

Period 2

Period 2 title	Extension Phase
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Blinding implementation details:

Open label Extension Phase

Arms

Arm title	Avatrombopag
Arm description:	
Avatrombopag	
Arm type	Active comparator
Investigational medicinal product name	Avatrombopag
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet, Powder for oral suspension
Routes of administration	Oral use

Dosage and administration details:

Subjects received avatrombopag or matching placebo as either the film-coated oral tablet or the powder for oral suspension. The powder for oral suspension was contained in a capsule that was to be opened to sprinkle the contents into an appropriate vehicle to prepare the suspension. No partial dosing from the capsule was allowed; the entire contents were to be used to prepare the suspension. On Day 1, Cohort 1 (≥ 12 to < 18 years old) and Cohort 2 (≥ 6 to < 12 years old) had a starting dose of avatrombopag of 20 mg once daily, administered as an oral tablet, consistent with the approved adult dosing. The starting dose for Cohort 3 (≥ 1 to < 6 years old) was 10 mg once daily administered as an oral suspension. The dose of study drug was to be titrated up or down based on the subject's platelet count to maintain a platelet count between ≥ 50 and $\leq 150 \times 10^9/L$.

Number of subjects in period 2 ^[1] ^[2]	Avatrombopag
Started	44
Completed	49
Not completed	24
Consent withdrawn by subject	3
Subject non-compliance	1
Adverse event, non-fatal	5
Sponsor request	6
Lack of efficacy	9
Joined	29
Transferred in from other group/arm	29

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Subjects may enter the extension phase even if they discontinue the core phase as per the protocol this is the definition of who enters: Subjects who complete the 12 week Core Phase of the study, or who meet the stopping criteria as defined in Section 5.3 of the protocol and are discontinued from the Core Phase, will be eligible to enter the open-label Extension Phase, if they continue to meet the inclusion criteria and do not meet any exclusion criteria for this phase of the study.

[2] - The number of subjects transferring in and out of the arms in the period are not the same. It is expected the net number of transfers in and out of the arms in a period, will be zero.

Justification: Subjects may enter the extension phase even if they discontinue the core phase as per the protocol. The subjects who discontinued the core phase had to be listed in the extension phase as transferred into the extension phase. All of these subjects didn't have to discontinue the extension phase so it will not equal zero.

Baseline characteristics

Reporting groups

Reporting group title	Avatrombopag
Reporting group description: -	
Reporting group title	Placebo
Reporting group description: -	

Reporting group values	Avatrombopag	Placebo	Total
Number of subjects	54	21	75
Age categorical Units: Subjects			
Infants and toddlers (28 days-23 months)	1	0	1
Children (2-11 years)	32	13	45
Adolescents (12-17 years)	21	8	29
Age continuous Units: years			
arithmetic mean	8.9	9.9	
standard deviation	± 4.36	± 4.13	-
Gender categorical Units: Subjects			
Female	24	12	36
Male	30	9	39

Subject analysis sets

Subject analysis set title	Full Analysis Set
Subject analysis set type	Full analysis
Subject analysis set description: All randomized subjects.	

Reporting group values	Full Analysis Set		
Number of subjects	75		
Age categorical Units: Subjects			
Infants and toddlers (28 days-23 months)	1		
Children (2-11 years)	45		
Adolescents (12-17 years)	29		
Age continuous Units: years			
arithmetic mean			
standard deviation	±		
Gender categorical Units: Subjects			
Female			
Male			

End points

End points reporting groups

Reporting group title	Avatrombopag
Reporting group description: -	
Reporting group title	Placebo
Reporting group description: -	
Reporting group title	Avatrombopag
Reporting group description:	
Avatrombopag	
Subject analysis set title	Full Analysis Set
Subject analysis set type	Full analysis
Subject analysis set description:	
All randomized subjects.	

Primary: Durable Platelet Response

End point title	Durable Platelet Response
End point description:	
The primary efficacy endpoint was durable platelet response as defined by the proportion of subjects achieving at least 6 out of 8 weekly platelet counts $\geq 50 \times 10^9/L$ during the last 8 weeks of the 12-week Treatment Period in the Core Phase in the absence of rescue medication.	
End point type	Primary
End point timeframe:	
12 Weeks	

End point values	Avatrombopag	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	54	21		
Units: Percentage				
Yes	15	0		
No	39	21		

Statistical analyses

Statistical analysis title	Durable Platelet Response
Comparison groups	Avatrombopag v Placebo
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	equivalence
P-value	= 0.0077
Method	Fisher exact

Primary: Platelet Response

End point title	Platelet Response
End point description:	
Platelet response was defined as having at least 2 consecutive platelet assessments $\geq 50 \times 10^9/L$ over the 12 weeks of treatment in the Core Phase in the absence of rescue medication.	
End point type	Primary
End point timeframe:	
12 Weeks	

End point values	Avatrombopag	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	54	21		
Units: Percentage				
Yes	44	0		
No	10	21		

Statistical analyses

Statistical analysis title	Platelet Response - FAS
Comparison groups	Avatrombopag v Placebo
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	equivalence
P-value	= 0.0067
Method	Fisher exact

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Core Phase - 12 weeks, Extension Phase - End of Study

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	26.1
--------------------	------

Reporting groups

Reporting group title	Avatrombopag
-----------------------	--------------

Reporting group description: -

Reporting group title	Placebo
-----------------------	---------

Reporting group description: -

Reporting group title	Open Label Extension
-----------------------	----------------------

Reporting group description:

Adverse Events reported through the End of Study visit.

Serious adverse events	Avatrombopag	Placebo	Open Label Extension
Total subjects affected by serious adverse events			
subjects affected / exposed	5 / 54 (9.26%)	1 / 21 (4.76%)	22 / 73 (30.14%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Injury, poisoning and procedural complications			
Abdominal Injury			
subjects affected / exposed	0 / 54 (0.00%)	0 / 21 (0.00%)	1 / 73 (1.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Head injury			
subjects affected / exposed	0 / 54 (0.00%)	0 / 21 (0.00%)	1 / 73 (1.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 54 (0.00%)	0 / 21 (0.00%)	1 / 73 (1.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			

Headache			
subjects affected / exposed	1 / 54 (1.85%)	0 / 21 (0.00%)	0 / 73 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysarthria			
subjects affected / exposed	0 / 54 (0.00%)	0 / 21 (0.00%)	11 / 73 (15.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paraesthesia			
subjects affected / exposed	0 / 54 (0.00%)	0 / 21 (0.00%)	1 / 73 (1.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tethered cord syndrome			
subjects affected / exposed	0 / 54 (0.00%)	0 / 21 (0.00%)	1 / 73 (1.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Immune thrombocytopenia			
subjects affected / exposed	1 / 54 (1.85%)	0 / 21 (0.00%)	1 / 73 (1.37%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytosis			
subjects affected / exposed	1 / 54 (1.85%)	0 / 21 (0.00%)	2 / 73 (2.74%)
occurrences causally related to treatment / all	1 / 1	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aplastic Anaemia			
subjects affected / exposed	0 / 54 (0.00%)	0 / 21 (0.00%)	1 / 73 (1.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone Marrow Disorder			
subjects affected / exposed	0 / 54 (0.00%)	0 / 21 (0.00%)	1 / 73 (1.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone Marrow Reticulin Fibrosis			

subjects affected / exposed	0 / 54 (0.00%)	0 / 21 (0.00%)	1 / 73 (1.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			
subjects affected / exposed	0 / 54 (0.00%)	0 / 21 (0.00%)	1 / 73 (1.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 54 (0.00%)	0 / 21 (0.00%)	4 / 73 (5.48%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Influenza like illness			
subjects affected / exposed	0 / 54 (0.00%)	0 / 21 (0.00%)	1 / 73 (1.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mucosal haemorrhage			
subjects affected / exposed	0 / 54 (0.00%)	0 / 21 (0.00%)	2 / 73 (2.74%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Hypogammaglobulinaemia			
subjects affected / exposed	0 / 54 (0.00%)	0 / 21 (0.00%)	1 / 73 (1.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Mouth haemorrhage			
subjects affected / exposed	1 / 54 (1.85%)	1 / 21 (4.76%)	0 / 73 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oral purpura			
subjects affected / exposed	1 / 54 (1.85%)	0 / 21 (0.00%)	0 / 73 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Rectal haemorrhage			
subjects affected / exposed	1 / 54 (1.85%)	0 / 21 (0.00%)	1 / 73 (1.37%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dental caries			
subjects affected / exposed	0 / 54 (0.00%)	0 / 21 (0.00%)	1 / 73 (1.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	0 / 54 (0.00%)	0 / 21 (0.00%)	1 / 73 (1.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Heavy menstrual bleeding			
subjects affected / exposed	0 / 54 (0.00%)	0 / 21 (0.00%)	1 / 73 (1.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vaginal haemorrhage			
subjects affected / exposed	0 / 54 (0.00%)	0 / 21 (0.00%)	1 / 73 (1.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Epistaxis			
subjects affected / exposed	1 / 54 (1.85%)	0 / 21 (0.00%)	4 / 73 (5.48%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Skin haemorrhage			
subjects affected / exposed	0 / 54 (0.00%)	1 / 21 (4.76%)	0 / 73 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Petechiae			

subjects affected / exposed	0 / 54 (0.00%)	0 / 21 (0.00%)	1 / 73 (1.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urticaria			
subjects affected / exposed	0 / 54 (0.00%)	0 / 21 (0.00%)	1 / 73 (1.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 54 (0.00%)	0 / 21 (0.00%)	1 / 73 (1.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 54 (0.00%)	0 / 21 (0.00%)	2 / 73 (2.74%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			
subjects affected / exposed	0 / 54 (0.00%)	0 / 21 (0.00%)	1 / 73 (1.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Avatrombopag	Placebo	Open Label Extension
Total subjects affected by non-serious adverse events			
subjects affected / exposed	50 / 54 (92.59%)	16 / 21 (76.19%)	71 / 73 (97.26%)
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	3 / 54 (5.56%)	1 / 21 (4.76%)	4 / 73 (5.48%)
occurrences (all)	7	1	22
Head injury			
subjects affected / exposed	1 / 54 (1.85%)	0 / 21 (0.00%)	4 / 73 (5.48%)
occurrences (all)	1	0	5
Joint injury			

subjects affected / exposed occurrences (all)	1 / 54 (1.85%) 1	0 / 21 (0.00%) 0	4 / 73 (5.48%) 4
Vascular disorders Haematoma subjects affected / exposed occurrences (all)	3 / 54 (5.56%) 3	3 / 21 (14.29%) 6	4 / 73 (5.48%) 9
Nervous system disorders Headache subjects affected / exposed occurrences (all)	10 / 54 (18.52%) 22	4 / 21 (19.05%) 4	17 / 73 (23.29%) 44
General disorders and administration site conditions Pyrexia subjects affected / exposed occurrences (all) Fatigue subjects affected / exposed occurrences (all)	9 / 54 (16.67%) 9 1 / 54 (1.85%) 1	0 / 21 (0.00%) 0 0 / 21 (0.00%) 0	18 / 73 (24.66%) 32 4 / 73 (5.48%) 7
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all) Thrombocytopenia subjects affected / exposed occurrences (all)	1 / 54 (1.85%) 1 0 / 54 (0.00%) 0	1 / 21 (4.76%) 1 1 / 21 (4.76%) 3	4 / 73 (5.48%) 9 4 / 73 (5.48%) 13
Gastrointestinal disorders Diarrhoea subjects affected / exposed occurrences (all) Vomiting subjects affected / exposed occurrences (all) Abdominal Pain subjects affected / exposed occurrences (all) Gingival bleeding	4 / 54 (7.41%) 5 4 / 54 (7.41%) 6 3 / 54 (5.56%) 3	0 / 21 (0.00%) 0 0 / 21 (0.00%) 0 0 / 21 (0.00%) 0	12 / 73 (16.44%) 18 8 / 73 (10.96%) 17 7 / 73 (9.59%) 16

subjects affected / exposed	2 / 54 (3.70%)	2 / 21 (9.52%)	3 / 73 (4.11%)
occurrences (all)	2	3	3
Rectal haemorrhage			
subjects affected / exposed	0 / 54 (0.00%)	2 / 21 (9.52%)	1 / 73 (1.37%)
occurrences (all)	0	2	1
Abdominal pain upper			
subjects affected / exposed	0 / 54 (0.00%)	0 / 21 (0.00%)	8 / 73 (10.96%)
occurrences (all)	0	0	11
Nausea			
subjects affected / exposed	2 / 54 (3.70%)	0 / 21 (0.00%)	9 / 73 (12.33%)
occurrences (all)	5	0	12
Toothache			
subjects affected / exposed	0 / 54 (0.00%)	0 / 21 (0.00%)	4 / 73 (5.48%)
occurrences (all)	0	0	6
Respiratory, thoracic and mediastinal disorders			
Epistaxis			
subjects affected / exposed	12 / 54 (22.22%)	4 / 21 (19.05%)	17 / 73 (23.29%)
occurrences (all)	30	9	154
Cough			
subjects affected / exposed	9 / 54 (16.67%)	0 / 21 (0.00%)	20 / 73 (27.40%)
occurrences (all)	11	0	57
Oropharyngeal pain			
subjects affected / exposed	7 / 54 (12.96%)	0 / 21 (0.00%)	12 / 73 (16.44%)
occurrences (all)	7	0	17
Rhinorrhoea			
subjects affected / exposed	3 / 54 (5.56%)	0 / 21 (0.00%)	10 / 73 (13.70%)
occurrences (all)	3	0	11
Nasal congestion			
subjects affected / exposed	2 / 54 (3.70%)	0 / 21 (0.00%)	8 / 73 (10.96%)
occurrences (all)	3	0	22
Skin and subcutaneous tissue disorders			
Petechiae			
subjects affected / exposed	14 / 54 (25.93%)	6 / 21 (28.57%)	9 / 73 (12.33%)
occurrences (all)	20	6	16
Ecchymosis			

subjects affected / exposed occurrences (all)	10 / 54 (18.52%) 19	1 / 21 (4.76%) 1	9 / 73 (12.33%) 24
Dry skin subjects affected / exposed occurrences (all)	0 / 54 (0.00%) 0	0 / 21 (0.00%) 0	4 / 73 (5.48%) 4
Pruritus subjects affected / exposed occurrences (all)	0 / 54 (0.00%) 0	1 / 21 (4.76%) 1	4 / 73 (5.48%) 6
Rash subjects affected / exposed occurrences (all)	0 / 54 (0.00%) 0	0 / 21 (0.00%) 0	5 / 73 (6.85%) 7
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	4 / 54 (7.41%) 6	0 / 21 (0.00%) 0	4 / 73 (5.48%) 10
Pain in extremity subjects affected / exposed occurrences (all)	3 / 54 (5.56%) 4	0 / 21 (0.00%) 0	2 / 73 (2.74%) 2
Infections and infestations			
Upper respiratory tract infection subjects affected / exposed occurrences (all)	6 / 54 (11.11%) 6	2 / 21 (9.52%) 2	30 / 73 (41.10%) 75
COVID-19 subjects affected / exposed occurrences (all)	4 / 54 (7.41%) 4	1 / 21 (4.76%) 1	3 / 73 (4.11%) 4
Nasopharyngitis subjects affected / exposed occurrences (all)	4 / 54 (7.41%) 5	0 / 21 (0.00%) 0	13 / 73 (17.81%) 20
Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	3 / 54 (5.56%) 5	0 / 21 (0.00%) 0	6 / 73 (8.22%) 12
Gastroenteritis subjects affected / exposed occurrences (all)	0 / 54 (0.00%) 0	0 / 21 (0.00%) 0	7 / 73 (9.59%) 11
Influenza			

subjects affected / exposed	0 / 54 (0.00%)	0 / 21 (0.00%)	6 / 73 (8.22%)
occurrences (all)	0	0	7
Pharyngitis			
subjects affected / exposed	1 / 54 (1.85%)	0 / 21 (0.00%)	5 / 73 (6.85%)
occurrences (all)	1	0	11
Sinusitis			
subjects affected / exposed	0 / 54 (0.00%)	0 / 21 (0.00%)	5 / 73 (6.85%)
occurrences (all)	0	0	5
Urinary tract infection			
subjects affected / exposed	0 / 54 (0.00%)	0 / 21 (0.00%)	4 / 73 (5.48%)
occurrences (all)	0	0	5
Viral infection			
subjects affected / exposed	2 / 54 (3.70%)	0 / 21 (0.00%)	4 / 73 (5.48%)
occurrences (all)	2	0	5
Rhinitis			
subjects affected / exposed	0 / 54 (0.00%)	0 / 21 (0.00%)	7 / 73 (9.59%)
occurrences (all)	0	0	16
Metabolism and nutrition disorders			
Iron deficiency			
subjects affected / exposed	1 / 54 (1.85%)	0 / 21 (0.00%)	4 / 73 (5.48%)
occurrences (all)	1	0	5

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
17 December 2020	Amendment 1 refined several inclusion and exclusion criteria, clarified the allowable contraception methods, aligned the definition of a lack of treatment effect in the Extension Phase with the Core Phase definition, and confirmed that a protocol amendment would be implemented if two subjects in Cohort 3 require medical monitor approved dose escalations above 20 mg daily.
02 November 2021	Amendment 2 updated the sponsor name, and clarified corticosteroid use prior to Baseline, the minimum subject age at Baseline, and the timing of serial PK sampling.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported

Online references

<http://www.ncbi.nlm.nih.gov/pubmed/40418942>

<http://www.ncbi.nlm.nih.gov/pubmed/41411046>